DNAJC3-AS1 Is Associated with Proliferation, Metastasis, and Poor Prognosis of Breast Cancer

• Published in: Disease markers Vol. 2021; pp. 3443474 - 8
• Main Authors: Zhang, Yi, Li, Jing-jing, Luo, Bo, Guo, Xiao-fei, Liu, Jian-xin, Yang, Shun-shi
• Format: Journal Article
• Language: English
• Published: United States Hindawi 2021; Hindawi Limited
• Subjects: Apoptosis; Assaying; Biomarkers; Breast cancer; Cancer therapies; Cell proliferation; Cholecystokinin; Diagnostic systems; Genomes; Lymph nodes; Medical prognosis; Membranes; Metastases; Metastasis; Prognosis; Survival; Tumors; Beijing China; United States > US; China
• ISSN: 0278-0240; 1875-8630; 1875-8630
• DOI: 10.1155/2021/3443474

Objective. Long noncoding RNA DNAJC3-AS1 (DNAJC3-AS1) was a newly identified tumor-related lncRNA. The aim of the present study was to explore the prognostic value and diagnostic of DNAJC3-AS1 (DNAJC3-AS1) expression in breast cancer (BC) patients. Patients and Methods. The expression of DNAJC3-AS1 was detected in 170 BC tissues and matched normal breast samples by qRT-PCR. The diagnostic value of DNAJC3-AS1 was examined by receiver-operating characteristic (ROC) assays. The correlation of DNAJC3-AS1 with clinicopathological features and prognosis was also statistically analyzed. CCK-8 assays, colony formation assays, and Transwell assays were applied to examine the potential function of DNAJC3-AS1 on tumor progression. Western blot was used to examine the expression of EMT-related proteins. Results. The expression of DNAJC3-AS1 in BC specimens was higher than that in the adjacent nontumor tissues (p<0.01). Diagnostic assays revealed that DNAJC3-AS1 has considerable diagnostic accuracy, with an area under the ROC curve (AUC) of 0.7457 (p<0.001). High DNAJC3-AS1 expression was positively associated with lymph node metastasis (p=0.010) and clinical stage (p=0.023). A survival study revealed that patients with high DNAJC3-AS1 expression had shorter overall survival (p=0.0067) and disease-free survival (p<0.0001) than those with low DNAJC3-AS1 expression. More importantly, multivariate assays indicated that DNAJC3-AS1 was an independent prognostic factor in BC patients. Functional assays confirmed that silence of DNAJC3-AS1 distinctly suppressed the proliferation, metastasis, and EMT progress of BC cells. Conclusions. DNAJC3-AS1 may be a prognostic and diagnostic biomarker for BC patients.